Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from Biogen, which has a commercial relationship with the drugmaker, Reuters says. The hedge fund's founder, Alex Denner, one of three Sarissa candidates running for seats on the Alkermes board, on Monday said he would give up his board seat at Biogen. The move eliminates "any claim of conflict whatsoever," Sarissa wrote to Alkermes shareholders on Tuesday. Alkermes licensed a multiple sclerosis drug to Biogen for commercialization, and some analysts worried it would be problematic for Denner to potentially sit on both boards.